Geneos Wealth Management Inc. Purchases 442 Shares of Bristol Myers Squibb Company (NYSE:BMY)

Geneos Wealth Management Inc. grew its position in Bristol Myers Squibb Company (NYSE:BMY) by 0.5% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 96,397 shares of the biopharmaceutical company’s stock after acquiring an additional 442 shares during the period. Geneos Wealth Management Inc.’s holdings in Bristol Myers Squibb were worth $5,879,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently modified their holdings of BMY. Pinney & Scofield Inc. acquired a new stake in shares of Bristol Myers Squibb during the 4th quarter worth about $25,000. Park Square Financial Group LLC acquired a new stake in shares of Bristol Myers Squibb during the 4th quarter worth about $26,000. Transce3nd LLC acquired a new stake in shares of Bristol Myers Squibb during the 4th quarter worth about $28,000. Global Wealth Strategies & Associates lifted its stake in shares of Bristol Myers Squibb by 137.5% during the 1st quarter. Global Wealth Strategies & Associates now owns 475 shares of the biopharmaceutical company’s stock worth $29,000 after buying an additional 275 shares during the last quarter. Finally, Harel Insurance Investments & Financial Services Ltd. acquired a new stake in shares of Bristol Myers Squibb during the 1st quarter worth about $31,000. Institutional investors own 76.41% of the company’s stock.

Analyst Ratings Changes

A number of research firms have recently issued reports on BMY. Argus upgraded shares of Bristol Myers Squibb to a “hold” rating in a research note on Friday, April 25th. The Goldman Sachs Group restated a “neutral” rating and set a $55.00 target price (down previously from $67.00) on shares of Bristol Myers Squibb in a research note on Tuesday, April 8th. Morgan Stanley dropped their price objective on shares of Bristol Myers Squibb from $36.00 to $34.00 and set an “underweight” rating for the company in a research note on Thursday, July 10th. Cantor Fitzgerald reiterated a “neutral” rating and issued a $55.00 price objective on shares of Bristol Myers Squibb in a research note on Tuesday, April 22nd. Finally, Piper Sandler began coverage on shares of Bristol Myers Squibb in a research note on Tuesday, April 22nd. They issued an “overweight” rating and a $65.00 price objective for the company. Two investment analysts have rated the stock with a sell rating, twelve have given a hold rating, six have issued a buy rating and two have given a strong buy rating to the company. According to MarketBeat.com, Bristol Myers Squibb has an average rating of “Hold” and a consensus price target of $58.53.

Bristol Myers Squibb Stock Down 1.4%

Shares of NYSE BMY opened at $46.85 on Wednesday. The company has a market capitalization of $95.35 billion, a P/E ratio of 17.55, a price-to-earnings-growth ratio of 2.50 and a beta of 0.36. Bristol Myers Squibb Company has a 52-week low of $44.00 and a 52-week high of $63.33. The company has a debt-to-equity ratio of 2.65, a quick ratio of 1.17 and a current ratio of 1.28. The company’s 50 day moving average price is $47.65 and its 200-day moving average price is $52.49.

Bristol Myers Squibb Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, August 1st. Stockholders of record on Thursday, July 3rd will be given a $0.62 dividend. The ex-dividend date is Thursday, July 3rd. This represents a $2.48 dividend on an annualized basis and a dividend yield of 5.29%. Bristol Myers Squibb’s dividend payout ratio (DPR) is currently 92.88%.

Bristol Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.